Article Prototype #1 View Prototype #2 Tell Us What You Think
May 2, 2008 - Volume 133, Issue 3, pp. 462-474 PDF (1,758 KB)

A Dynamic Pathway for Calcium-Independent Activation of CaMKII by Methionine Oxidation

Jeffrey R. Erickson1
Mei-ling A. Joiner1
Xiaoqun Guan1
William Kutschke1
Jinying Yang1
Carmine V. Oddis5
Ryan K. Bartlett6
John S. Lowe1
Susan E. O'Donnell2
Nukhet Aykin-Burns3
Matthew C. Zimmerman3
Kathy Zimmerman9
Amy-Joan L. Ham7,8
Robert M. Weiss1,9
Douglas R. Spitz3
Madeline A. Shea2
Roger J. Colbran7
Peter J. Mohler1,4
, and
Mark E. Anderson1,4,*
Author Affiliations
1Department of Internal Medicine, Carver College of Medicine
2Department of Biochemistry, Carver College of Medicine
3Department of Radiation Oncology, Free Radical and Radiation Biology Program
4Department of Molecular Physiology and Biophysics, Carver College of Medicine
University of Iowa, Iowa City, IA, 52242-1109, USA
5Department of Internal Medicine, Vanderbilt University
6Department of Molecular Physiology and Biophysics, Vanderbilt University Medical Center
7Department of Biochemistry, Vanderbilt University
8The Mass Spectrometry Research Center, Vanderbilt University
Nashville, TN 37232-0615, USA
9Department of Veterans Affairs Medical Center, Iowa City, IA 52242-1109, USA

Article Highlights

  • Oxidation of methionine residues activates CaMKII
  • Angiotensin II induces CaMKII oxidation leading to cardiomyocyte death
  • CaMKII methionine oxidation is reversed by MsrA
  • Elevated CaMKII oxidation impairs heart function and worsens ischemic injury

Author Interview


Calcium/calmodulin (Ca2+/CaM)-dependent protein kinase II (CaMKII) couples increases in cellular Ca2+ to fundamental responses in excitable cells. CaMKII was identified over 20 years ago by activation dependence on Ca2+/CaM, but recent evidence shows that CaMKII activity is also enhanced by pro-oxidant conditions. Here we show that oxidation of paired regulatory domain methionine residues sustains CaMKII activity in the absence of Ca2+/CaM. CaMKII is activated by angiotensin II (AngII)-induced oxidation, leading to apoptosis in cardiomyocytes both in vitro and in vivo. CaMKII oxidation is reversed by methionine sulfoxide reductase A (MsrA), and MsrA-/- mice show exaggerated CaMKII oxidation and myocardial apoptosis, impaired cardiac function, and increased mortality after myocardial infarction. Our data demonstrate a dynamic mechanism for CaMKII activation by oxidation and highlight the critical importance of oxidation-dependent CaMKII activation to AngII and ischemic myocardial apoptosis.

The authors wish to acknowledge discussions with Dr. Botond Bonfi, Dr. Trudy Burns, Dr. Johannes Hell, Dr. David Murhammer, Dr. Stefan Strack, and Dr. Michael Welsh (University of Iowa) and technical contributions of Chantal Allamargot (University of Iowa Central Microscopy Research Facility). The authors also wish to acknowledge the graphic design contributions of Shawn Roach (University of Iowa). Mice lacking the MsrA gene were generously provided by Dr. Earl Stadtman of NIH (Bethesda, MD, USA). This work was funded by NIH R01 HL 079031, R01 HL 62494, and R01 HL 70250 (M.E.A.); NIH R01 HL084583 and R01 HL083422 and Pew Scholars Trust (P.J.M.); NIH R01 GM57001 (M.A.S.); NIH RR017369 (R.M.W.); UI CVC Interdisciplinary Research Fellowship (J.R.E.); UI Center for Biocatalysis and Bioprocessing Fellowship (S.E.O.); and the University of Iowa Research Foundation.

Oxidation Directly Activates CaMKII

CaMKII is activated by Ca2+/CaM, but autophosphorylation at T287 sustains catalytic activity after dissociation of Ca2+/CaM (Figure 1A) because the negatively charged phosphate prevents reassociation of the catalytic domain and autoinhibitory region (Hudmon and Schulman, 2002). CaMKII activity may also be enhanced by pro-oxidant conditions (Zhu et al., 2007); we therefore hypothesized that oxidation of the regulatory domain in the vicinity of T287 could sustain CaMKII catalytic activity by an analogous mechanism. Exposure of purified CaMKII to H2O2 in the absence of any pretreatment yielded no discernable CaMKII activity (Figure 1B). However, exposure to H2O2 after pretreatment with Ca2+/CaM yielded persistent CaMKII activation even in the presence of EGTA. These data suggest that Ca2+/CaM binding exposed a key segment of CaMKII for oxidation, and that oxidation interfered with the interaction of the autoinhibitory and catalytic domains. Activation of wild-type (WT) CaMKII by H2O2 was dose dependent (Figure 1C). The concentration of EGTA used was sufficient to block CaMKII activity without the addition of H2O2 (Figure 1B), suggesting that activity observed in the pro-oxidant condition was independent of sustained Ca2+/CaM binding.

Click to view full size image
Figure 1.CaMKII Is Activated by ROS

Pretreatment with Ca2+/CaM was also necessary for autophosphorylation-dependent CaMKII activation, indicating that autophosphorylation and oxidation of CaMKII occur by parallel mechanisms. CaMKII bearing a T287A substitution underwent normal Ca2+/CaM-dependent activation but did not maintain persistent Ca2+-independent activity in the presence of ATP (Figure 1D). However, the T287A mutant was activated by H2O2 (Figure 1C), and the extent of this activation was statistically indistinguishable at all but the highest concentration of H2O2 tested (1 mM).Weinterpret these observations as evidence that activation of CaMKII by ROS and autophosphorylation occur by a similar mechanism, but by independent modifications to nearby sites. Activation of the kinase by either mechanism requires the enzyme to be initially ‘‘opened’’ by Ca2+/CaM to allow access to the autoinhibitory domain for oxidation or autophosphorylation (Figures 1A and 1E). Either of these modifications can prevent subsequent interaction of the autoinhibitory region with the catalytic domain, providing for sustained Ca2+-independent activation of CaMKII. Consistent with these ideas, direct measurements of intrinsic fluorescence revealed that autophosphorylation and oxidation of CaMKII independently induce similar conformational changes in CaMKII (Figure S1).

Click to view full size image
Figure S1.Oxidation and autophosphorylation of CaMKII are associated with similar fluorescence shifts. (A) Sample emission fluorescence spectra of WT CaMKII after no treatment or in the presence of Ca2+/CaM, ATP, or H2O2. We observed no significant difference among CaMKII mutants for peak fluorescence with no treatment (n=3 assays/group, not shown). (B) M281/282V CaMKII mutants do not show a shift in emission fluorescence intensity at peak fluorescence after treatment with 100µM H2O2 (n=3 assays/group, * p<0.05 vs. WT no treatment). Response to Ca2+/CaM and ATP activation are unchanged.

Proteomic analysis of the synthetic peptide that contains the 281/282 methionine residues was used to probe for oxidative modification upon treatment with H2O2. We observed a clear decrease in the unoxidized form coupled with an increase in the various oxidized forms of this peptide based on the chromatographic traces and on the change in the number of observed spectra (Figure S2). In addition to the synthetic peptide, we analyzed the peptide containing the 281/282 methionine residues after treatment of the whole protein with H2O2 followed by trypsin cleavage. We were able to determine the relative change in oxidation of this peptide upon hydrogen peroxide treatment (Tables S1 and S2). The MS/MS spectra of the oxidized forms of the peptide were identical to those from the synthetic peptide, verifying that the oxidized peptide was correctly identified.

Click to view full size image
Figure S2.Unmodified and modified tandem MS (MS/MS) spectra of the 281/282 containing tryptic peptide STVASMMHR. The observed fragment ions are indicated on the sequence for each spectrum. Spectra were also observed for the peptide with one or two oxygens added to the peptide (data not shown). Asterisks indicate fragment ions that contain the mass shift in the ions due to the addition of the oxygens. (A) Unoxidized peptide designating b- and y-ions produced upon fragmentation. m/z = 510.24 (B) Peptide oxidized with one oxygen. m/z = 518.24 (C) Peptide oxidized with two oxygens. m/z = 526.24 (D) Peptide oxidized with three oxygens. m/z=534.24 (E) Peptide oxidized with four oxygens. m/z = 542.24.
Table S1.Oxidation of synthetic peptide methionines upon H2O2 treatment and trypsin digestion
Table S2.Oxidation of tryptically digested methionine-containing peptides after H2O2 treatment of intact protein
View Supplementary Tables (PDF 16K)

Given these observations and the recognized susceptibility of methionine residues to oxidation (Hoshi and Heinemann, 2001), we made methionine to valine mutations for the paired residues (M281/282V) andfor anothermethionine(M308V) intheCaM-binding region. Thesemutants were exposed to H2O2 and assayed for activity in the presence of EGTA (Figure 1C). The H2O2-dependent activation of CaMKII was preserved in the M308V mutant. However, oxidation-dependent CaMKII activity was completely abolished in the M281/282V and M281/282/308V mutants. Our data, obtained in cell-free assay conditions, point to direct oxidation of the M281/282 pair as the primary H2O2-dependent activation pathway for CaMKII. Importantly, all the methionine to valine mutants showed a normal activity response to autophosphorylation (Figure 1D), further supporting the concept that Ca2+-autonomous CaMKII activation by ROS or T287 autophosphorylation are independent events. While the paired methionine motif is conserved in the b, g, andd isoformsofCaMKII, the neuronal a isoform substitutes a cysteine residue for the first methionine of the pair (position 280 in CaMKIIa). The side chain of cysteine is also susceptible to oxidation. We generated a M281C mutant of CaMKIId to mimic the substitution in CaMKIIa. Additionally, we generated and purified CaMKIIa. Both the M281C CaMKIId mutant and the purified CaMKIIa were activated by H2O2, indicating that the cysteine substitution seen in CaMKIIa also supports ROS-dependent activation (Figure 1C). To further elucidate the role of M281 and M282 in ROS-dependent activation, these sites were individually mutated (Figure S3). The M282V mutation completely ablated oxidation-dependentactivation, while the M281V mutationpartially reduced activation by 65%, indicating that a single oxidation event within the regulatory domain is insufficient to activate CaMKII.

Click to view full size image
Figure S3.ROS-dependent activity is ablated by M281V or M282V point mutation. Wild type CaMKII shows increased activity in response to H2O2 treatment, while this dose dependent activation is not seen in the M281V and M282V mutants. (n=3 assays/group, * p<0.05 vs. WT no treatment)

Autophosphorylation at T287 dramatically increases the binding affinity of CaMKII for CaM, a phenomenon known as ‘‘CaM trapping’’ (Meyer et al., 1992). In the absence of ATP the Ca2+/CaM/CaMKII complex was very rapidly dissociated following addition of EGTA, independent of the redox state, as measured by fluorescence anisotropy of dansylated CaM (Figure S4A). CaMKII exposure to H2O2 for 10 min induced Ca2+/CaM-independent activity (as in Figure 1B) but also failed to induce CaM trapping (not shown). These observations indicate that under normal experimental conditions, oxidation of CaMKII is not sufficient to induce CaMtrapping. Dissociation ofCa2+/CaMfrom autophosporylated CaMKII and CaM was significantly slower than from nonphosphorylated enzyme, consistent withCaMtrapping. However, pretreatment withH2O2 prior to EGTA had no significant effect on the dissociation kinetics. Thus, oxidation of CaM or CaMKII does not prevent or enhance CaM trapping by autophosphorylated CaMKII. CaM trapping is reduced by phosphorylation of T306/307 (Colbran, 1993), so we investigated whether oxidation of M308 might prevent CaM trapping by a parallel mechanism. We did observe a significant slowing of dissociation of the CaM/CaMKII complex after H2O2 treatment of the M308 mutant (Figures S4B and S4C). These data suggest that the absence of CaM trapping during oxidation is partly due to M308.

Click to view full size image
Figure S4.Oxidation of CaMKII does not initiate CaM trapping during ROS-dependent CaMKII activation. (A) Real time fluorescence anisotropy measurement of CaM after the addition of CaCl2, CaMKII, and EGTA (black line). Addition of H2O2 prior to EGTA (red line) does not result in CaM trapping. CaM trapping is seen when ATP is present (blue and green lines). (B) In contrast to WT CaMKII, an M308V mutant shows slowed Ca2+/CaM/CaMKII dissociation after treatment with H2O2. (C) Half time to baseline fluorescence after addition of EGTA for Ca2+/CaM/CaMKII dissociation with WT or M308V CaMKII (n=3 trials/group, * p<0.05 vs. half time for CaMKII in buffer only). (D) Pretreatment of CaMKII with iodoacetic acid blocks cysteine oxidation but does not affect ROSdependent activity. Mutation of C290 does not affect CaMKII activity responses to H2O2.

It seemed possible that conditions capable of oxidizing methionine residues would also oxidize unprotected cysteine residues. Although mutation of methionine residues at 281 and 282 was sufficient to completely ablate ROS-dependent activation of CaMKII, we created a C290V mutant to determine whether this cysteine residue within the CaMKII regulatory domain could also play a role. Both the Ca2+/CaM-dependent activity and the ROS-dependent activity of the C290V mutant were indistinguishable from that with WT CaMKII (Figure S4D). Our finding that oxidation of paired amino acids (M281/282 in CaMKIId) was required for activation by H2O2 supports a view that oxidation of a lone residue is insufficient to confer Ca2+/CaM-autonomous CaMKII activity. In order to comprehensively test the potential role of all accessible cysteines in contributing to oxidation-dependent CaMKII activity we measured CaMKII activity responses to H2O2 in the presence of iodoacetic acid, a reagent that blocks oxidation of unprotected cysteine residues (Zangerle et al., 1992). Cysteine-protected CaMKIId showed equivalent H2O2 activity responses compared to CaMKIId without iodoacetic acid (Figure S2D). We used an established colorometric assay to quantify the available cysteine residues and verify that cysteine protection by iodoacetic acid was effective. Our results confirmed that most or all of the 11 cysteines in CaMKIId were accessible to the Ellman’s reagent after Ca2+/ CaM binding, while treatment with iodoacetic acid blocked the accessibility of cysteine residues to biochemical modification (data not shown). Taken together, these findings demonstrate that oxidative activation of CaMKIId is independent of cysteines.

Oxidation of CaMKII Occurs In Vivo

We developed an immune serum against oxidized M281/282 to detect ROS effects on CaMKII in vivo. We validated the fidelity of the antiserum using purified CaMKII protein by immunoblotting against WT CaMKII and the M281/282V mutant in control conditions and after treatment with H2O2 or Ca2+/CaM/ATP. Blots were also assayed with a phospho- and site-specific antibody against T287 (p-287). WT CaMKII exposed to H2O2 after pretreatment with Ca2+/CaM showed significant reactivity to our oxidized M281/282 antiserum, but untreated and T287-phosphorylated CaMKII samples were not recognized by our antiserum (Figure 2A). The M281/282Vmutant hadminimal reactivity to our antiserumamong the three treatments. These findings demonstrated that phospho-T287 and oxidized M281/282 were immunologically distinct sites. We performed additional immunoblots in which oxidized CaMKII was probed with the antiserum along with increasing concentrations of the peptide antigen (Figure 2B). Band intensity decreased with increasing peptide concentration, indicating that the immune serum was specific for oxidized CaMKII.

Click to view full size image
Figure 2.AngII Induces Oxidation of CaMKII In Vivo

To determine the role of CaMKII oxidation in apoptosis, mice were treated with saline, AngII, or isoproterenol (Iso) for 1 week, and transverse heart sections from these mice were probed for the production of oxidized CaMKII in vivo. WT mice treated with AngII produced more oxidized CaMKII than those treated with saline or Iso (Figure 2C). Total CaMKII immunoreactivity remained constant regardless of treatment. Conversely, mice lacking a critical subunit of NADPH oxidase (p47-/-) did not show increased levels of oxidized CaMKII in response to AngII. The p47-/- mice did not assemble the ROS-producing complex NADPH oxidase (Munzel and Keaney, 2001), the main source of ROS due to AngII stimulation in many cell types (Lyle and Griendling, 2006). Heart sections from WT mice showed increased staining for T287-phosphorylated CaMKII after AngII treatment, while p47-/- mice were unaffected (Figure S5). Other studies have suggested that protein phosphatase activity is decreased by pro-oxidant conditions (Howe et al., 2004), indicating the possibility of coordinate activation of CaMKII both by direct oxidation at the Met281/282 sites and by phosphatase inactivation leading to increased phosphorylation at the T287 site.

Click to view full size image
Figure S5.Wild type heart sections have increased T287-phosphorylated CaMKII after AngII treatment. Wild type and p47-/- mice were treated with AngII (3mg/kg/day) for 1 week. Heart sections from these mice were stained with an antibody against T287-phosphorylated or total CaMKII.

We also homogenized hearts from mice treated with saline, AngII, or Iso, and whole heart lysates were analyzed by immunoblot for oxidized CaMKII. While total CaMKII was not significantly different among the three treatment groups, heart lysates from mice treated with AngII showed significantly increased oxidized CaMKII levels (Figure 2D). Taken together, these findings demonstrate that oxidation of CaMKII occurs in vivo, and that elevated levels of AngII increase CaMKII oxidation at M281/282 compared to saline or Iso.

AngII Triggers ROS Production and CaMKII-Dependent Apoptosis in Cardiomyocytes

Given our results, we hypothesized that cells deficient in ROS production or CaMKII activity would be resistant to AngII-mediated apoptosis. We treated cardiomyocytes from mice that express an inhibitory peptide against CaMKII (AC3-I, Zhang et al., 2005) with 100 nM AngII for 24 hr in parallel with isolated cardiomyocytes fromWTand p47-/- mice. AngII caused a significant increase in the percent of TUNEL-positive nuclei inWT cells but had no significant effect in p47-/- or AC3-I cardiomyocytes (Figure 3A). Activity assays for caspase-3, a downstream target enzyme in the CaMKII apoptotic signaling pathway in heart, recapitulated the results from the TUNEL assay (Figure 3B). Importantly, direct addition of ROS in the form of H2O2 caused significant apoptosis in p47-/- cells, demonstrating that their resistance to AngII-induced apoptosis is a result of impaired ability to produce ROS rather than a lack of sensitivity to ROS. The apoptotic effect of H2O2 in AC3-I cells was blunted by more than half compared to WT or p47-/- cells (Figure 3A), indicating the critical importance of CaMKII activation to ROS- and Iso-dependent apoptosis.

Click to view full size image
Figure 3.AngII Increases ROS Production and Apoptosis by a CaMKII-Dependent Pathway in Cardiomyocytes

In order to validate the connection between AngII and ROS in our experimental model, we treated isolated cardiomyocytes from WT and p47-/- mice with 100 nM AngII and monitored production of ROS by imaging DHE, a fluorescent reporter for superoxide and hydrogen peroxide (Figure 3C). We also incubated WT cardiomyocytes with fura-2 AM, a cell-permeant calcium indicator, to observe changes in intracellular Ca2+ ([Ca2+]i). Treatment with AngII caused a significant increase in ROS production in WT but not in p47-/- cardiomyocytes (Figure 3D). On the other hand, increases in [Ca2+]i were significantly less after AngII compared to Iso treatment (Figures 3E and 3F) for cardiomyocytes from both WT and p47-/- mice. These data show that AngII signaling predominantly increases ROS, while Iso predominantly increases [Ca2+]i under our experimental conditions.

CaMKII Knockdown Prevents AngII- and Iso-Induced Apoptosis

In order to further test the role of CaMKII and specifically define the effects of M281/282 on myocardial apoptosis, we used a knockdown and replacement strategy in cultured neonatal cardiomyocytes. Rat cardiomyocytes were cultured and treated with shRNA-encoding lentivirus against rat CaMKIId. After 48 hr CaMKII expression was significantly reduced, as measured by immunoblot and activity assays (Figure 4A). Cells were then transduced with lentivirus encoding shRNA-resistant WT or M281/282V mutant CaMKII. Control cells were transduced with GFP-encoding lentivirus. After 48 hr, cells transduced with CaMKII rescue constructs showed significant recovery of CaMKII expression compared to control cells. Addition of Ca2+/ CaM to lysates from cells transduced with either CaMKII-encoding virus had similar total activity to native cells. However, H2O2-induced activity was only rescued in cells expressing the WT CaMKII construct. These cellular studies support our earlier finding with molecular CaMKII (Figure 1) by showing that oxidation of M281/282 is critical for ROS-triggered CaMKII activity. In addition, this strategy created cardiomyocytes that express ROS-resistant CaMKII, providing a system for investigating ROS- and CaMKII-dependent apoptosis.

Click to view full size image
Figure 4.AngII-Induced Apoptosis Is Blocked by CaMKII Silencing

Cardiomyocytes treated with shRNAs/CaMKIId-encoding lentivirus were exposed to saline, AngII, or Iso as above (Figure 4B). The apoptotic response to AngII and Iso was significantly attenuated in CaMKII knockdown cells compared to myocytes without shRNA. Moreover, expression of shRNA-resistant WT CaMKII fully rescued apoptotic responses to both agonists (Figure 4C). In contrast, expression of the ROS-resistant M281/282V CaMKII mutant rescued the apoptotic response to Iso but, importantly, failed to rescue the apoptotic response to AngII after 24 hr (Figure 4C). Cells expressing the M281/282V CaMKII remained susceptible to Iso-induced apoptosis (Figures 4B and 4C), indicating that elimination of these residues does not affect activation of CaMKII by catecholamine stimulation. These cellular studies are performed in a complex biological environment compared to studies with isolated CaMKII but nevertheless support the concept that direct oxidation of CaMKII by AngII is sufficient to confer enhanced CaMKII activity and trigger apoptosis.

ROS Production and CaMKII Activity Are Critical for AngII-Mediated Cardiac Apoptosis In Vivo

Intracellular ROS levels increase dramatically in models of structural heart disease (Hare, 2001), particularly those initiated by AngII (Tojo et al., 2002). Stimulation by AngII leads to activation of the NADPH oxidase complex, increasing intracellular superoxide and hydrogen peroxide levels. To establish an in vivo context for our previous findings and to test the role of CaMKII in AngII-stimulated cardiac apoptosis, p47-/-, AC3-I, and WT mice were treated with saline, AngII, or Iso for 1 week. Transverse heart sections from these mice were stained for evidence of apoptosis. After 1 week WT mice treated with either AngII or Iso showed significant cardiac apoptosis, as determined by TUNEL staining of heart sections (Figure 5). The p47-/- mice had no significant increase in cardiac apoptosis after treatment with AngII, most likely because these mice were unable to produce ROS in response to AngII stimulation (Figure 3D). However, the p47-/- mice showed a preserved apoptotic response to Iso, suggesting that Iso-induced apoptosis occurs independently of oxidative stress generated by NADPH oxidase in vivo under these conditions. In contrast, the AC3-I mice with CaMKII inhibition were resistant to apoptosis induced by either AngII or Iso, indicating that CaMKII is a necessary signal element for apoptosis initiated by AngII or Iso in vivo.

Click to view full size image
Figure 5.AngII Causes Cardiac Apoptosis In Vivo via a ROS- and CaMKII-Mediated Pathway

Increased CaMKII Oxidation, Apoptosis, Cardiac Dysfunction, and Death in MsrA-/- Mice

Methionine oxidation is specifically reversed by MsrA (Weissbach et al., 2002), so we hypothesized that MsrA-/- mice would show enhanced vulnerability to AngII-mediated CaMKII oxidation and apoptosis. In order to test this idea we implanted MsrA-/- and WT control mice with AngII- or saline-eluting osmotic minipumps. Hearts from MsrA-/- mice treated with AngII in vivo showed significantly more CaMKII oxidation (Figures 6A and 6B) and increased TUNEL staining (Figure 6C) compared to saline-treated MsrA-/- mice and to saline- or AngII-treated control hearts. The increased CaMKII oxidation by AngII in MsrA-/- hearts showed that CaMKII oxidation is dynamically regulated by MsrA in myocardium in vivo and suggested that MsrA-/- mice would be more vulnerable to severe myocardial stress due to increased methionine oxidation. Myocardial infarction is the most common cause of sudden cardiac death and heart failure in patients, and p47-/- (Doerries et al., 2007) and AC3-I mice (Zhang et al., 2005) are protected from left ventricular dilation and dysfunction after myocardial infarction surgery, suggesting that ROS activation of CaMKII may be important in myocardial infarction. In order to test if CaMKII oxidation and apoptosis were regulated by NADPH oxidase and MsrA in the setting of myocardial infarction, we subjected MsrA-/-, p47-/-, and WT mice to myocardial infarction surgery. MsrA-/- mice showed significantly more CaMKII oxidation (Figures 7A and 7B) and myocardial apoptosis (Figure 7C) compared to WT and p47-/- mice. These data indicate that CaMKII oxidation is dynamically regulated by NADPH oxidase and MsrA in the setting of myocardial infarction. We performed myocardial infarction surgery on a larger cohort of MsrA-/- and WT control mice to determine if increased CaMKII oxidation and apoptosis in MsrA-/- mice translated into poorer functional outcomes.

Click to view full size image
Figure 6.MsrA-/- Mice Have Increased Susceptibility to AngII Mediated Apoptosis
Click to view full size image
Figure 7.Mice Lacking MsrA Have Increased CaMKII Oxidation, Apoptosis, Reduced Survival, and Impaired Heart Function after Myocardial Infarction
Fig 1View supplemental images Fig 2View supplemental images Fig 3View supplemental images Fig 4 Fig 5 Fig 6 Fig 7 Fig 8
Fig 1 Supplementary Figures: Fig S1 Fig S2 Fig S3 Fig S4
Fig 2 Supplementary Figures: Fig S5 Fig S7
Fig 3 Supplementary Figure: Fig S6


traditional display here
Analysis of 51 References:

1978 (1) 1985 (1) 1986 (1) 1990 (1) 1992 (3) 1993 (1) 1995 (1) 1997 (1) 1999 (1) 2000 (3) 2001 (5) 2002 (7) 2003 (4) 2004 (5) 2005 (3) 2006 (10) 2007 (3)
1960     1970       1980       1990        2000

Introduction (14)
Results (14)
Discussion (24)
Experimental Procedures (7)

Fig 1 Supplementary Figures: Fig S1 Fig S2 Fig S3 Fig S4
Fig 2 Supplementary Figures: Fig S5 Fig S7
Fig 3 Supplementary Figure: Fig S6

Colbran, R.J. (1993). Inactivation of Ca2+/calmodulin-dependent protein kinase II by basal autophosphorylation. J. Biol. Chem. 268, 7163-7170.

Doerries, C., Grote, K., Hilfiker-Kleiner, D., Luchtefeld, M., Schaefer, A., Holland, S.M., Sorrentino, S., Manes, C., Schieffer, B., Drexler, H., and Landmesser, U. (2007). Critical role of the NAD(P)H oxidase subunit p47phox for left ventricular remodeling / dysfunction and survival after myocardial infarction. Circ. Res. 100, 894-903.

Hare, J.M. (2001). Oxidative stress and apoptosis in heart failure progression. Circ. Res. 89, 198-200.

Hoshi, T., and Heinemann, S.H. (2001). Regulation of cell function by methionine oxidation and reduction. J. Physiol. 531, 1-11.

Howe, C.J., Lahair, M.M., McCubrey, J.A., and Franklin, R.A. (2004). Redox regulation of the calcium/calmodulin-dependent protein kinases. J. Biol. Chem. 279, 44573-44581.

Hudmon, A., and Schulman, H. (2002). Structure-function of the multifunctional Ca2+/calmodulin-dependent protein kinase II. Biochem. J. 364, 593-611.

Lyle, A.N., and Griendling, K.K. (2006). Modulation of vascular smooth muscle signaling by reactive oxygen species. Physiology (Bethesda) 21, 269-280.

Meyer, T., Hanson, P.I., Stryer, L., and Schulman, H. (1992). Calmodulin trapping by calcium-calmodulin-dependent protein kinase. Science 256, 1199-1202.

Munzel, T., and Keaney, J.F., Jr. (2001). Are ACE inhibitors a magic bullet against oxidative stress? Circulation 104, 1571-1574.

Tojo, A., Onozato, M.L., Kobayashi, N., Goto, A., Matsuoka, H., and Fujita, T. (2002). Angiotensin II and oxidative stress in Dahl Salt-sensitive rat with heart failure. Hypertension 40, 834-839.

Weissbach, H., Etienne, F., Hoshi, T., Heinemann, S.H., Lowther, W.T., Matthews, B., St John, G., Nathan, C., and Brot, N. (2002). Peptide methionine sulfoxide reductase: structure, mechanism of action, and biological function. Arch. Biochem. Biophys. 397, 172-178.

Zangerle, L., Cuenod, M., Winterhalter, K.H., and Do, K.Q. (1992). Screening of thiol compounds: depolarization-induced release of glutathione and cysteine from rat brain slices. J. Neurochem. 59, 181-189.

Zhang, R., Khoo, M.S., Wu, Y., Yang, Y., Grueter, C.E., Ni, G., Price, E.E., Thiel, W., Guatimosim, S., Song, L.S., et al. (2005). Calmodulin kinase II inhibition protects against structural heart disease. Nat. Med. 11, 409-417.

Zhu, W.Z., Woo, A.Y., Yang, D.M., Cheng, H., Crow, M.T., and Xiao, R.P. (2007). Activation of CaMKII is a common intermediate of diverse death stimuli-induced heart muscle cell apoptosis. J. Biol. Chem. 282, 10833-10839.

Lorenzo Phelps
Institut Gustave Roussy, France
May 19, 2009
Etiam congue faucibus elit. Praesent volutpat. Integer placerat tristique magna. Praesent porttitor turpis sed leo. Sed sodales ullamcorper magna. Donec volutpat elit vel ligula. Sed ornare, risus at congue tristique, arcu nisl hendrerit nisl, non consectetur dui nunc rhoncus orci. Proin eleifend elementum purus. Suspendisse id quam nec lectus volutpat posuere. Pellentesque lectus mi, egestas sed, mattis a, aliquet sed, odio. Sed sit amet erat ut nisl laoreet ultrices. Duis gravida feugiat sapien. Mauris velit. Cras tempus. Aliquam in enim. Cras diam mauris, tincidunt id, iaculis eu, vestibulum a, eros. Nunc tempor magna et enim. Vestibulum viverra. Phasellus molestie quam sed ipsum. Phasellus massa nisl, imperdiet vel, accumsan sit amet, venenatis non, magna.
Prof. Sarah Lakhani
Memorial Sloan-Kettering Cancer Center, New York, NY
May 17, 2009
Curabitur porta pretium nulla. Proin id dolor ut velit fermentum ullamcorper. Sed metus lorem, ornare sit amet, bibendum et, tincidunt ut, nunc. Duis quam enim, adipiscing ut, cursus vel, feugiat ut, nisl. Vivamus odio elit, vehicula ut, adipiscing vitae, tincidunt hendrerit, erat. Donec felis pede, consectetur eu, malesuada non, volutpat a, nisi. Integer eget odio nec neque porttitor posuere. Nulla dolor. Nulla cursus, massa vel consequat blandit, dui quam eleifend nisi, volutpat adipiscing eros mi eget magna. Nunc aliquet dolor eget augue. Pellentesque eget elit. Maecenas lacinia.
John Sanderson
Professor of Clinical Cardiology
Queen Elizabeth Hospital, Birmingham UK
May 15, 2009
Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas. Cras vulputate hendrerit magna. Vestibulum fermentum ornare metus. Curabitur mollis diam sit amet sem. Mauris interdum sapien. Mauris tempus hendrerit ipsum. Nam purus. Maecenas ac sapien in sem posuere congue. Nulla dui lectus, congue in, hendrerit vel, tristique et, nibh. Phasellus elit. Vestibulum ultricies ipsum in diam. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Vestibulum sit amet purus non mauris malesuada cursus. Maecenas erat. Mauris ullamcorper.

Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Sed ut mauris vel pede malesuada bibendum. Cras imperdiet vehicula turpis. Cras magna. Donec diam. Proin ac est at metus mollis ornare. Morbi scelerisque quam id urna. Pellentesque id orci id tellus volutpat posuere. In volutpat mauris sed orci. Curabitur vel sem id felis ullamcorper suscipit. Sed nibh. Donec et eros. Vivamus ante nisl, auctor quis, vehicula consequat, posuere ut, ante. Etiam odio dolor, mattis at, elementum sit amet, congue non, ante. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus.
Your Comment:
Author Name Department Affiliation Articles on Scopus
1 Erickson, Jeffrey R. Department of Internal Medicine Carver College of Medicine 5
2 Joiner, Mei-ling A. Department of Internal Medicine Carver College of Medicine 1
3 Guan, Xiaoqun Department of Internal Medicine Carver College of Medicine 2
4 Kutschke, William Department of Internal Medicine Carver College of Medicine 8
5 Yang, Jinying Department of Internal Medicine Carver College of Medicine 5
6 Oddis, Carmine V. Department of Internal Medicine Vanderbilt University 87
7 Bartlett, Ryan K. Department of Molecular Physiology and Biophysics Vanderbilt University Medical Center 9
8 Lowe, John S. Department of Internal Medicine Carver College of Medicine 4
9 ODonnell, Susan E. Department of Biochemistry Carver College of Medicine 2
10 Aykin-Burns, Nukhet Department of Radiation Oncology Free Radical and Radiation Biology Program 9
11 Zimmerman, Matthew C. Department of Radiation Oncology Free Radical and Radiation Biology Program 8
12 Zimmerman, Kathy Department of Veterans Affairs Medical Center Iowa City, IA 52242-1109, USA 3
13 Ham, Amy-Joan L. Department of Biochemistry; The Mass Spectrometry Research Center Vanderbilt University 8
14 Weiss, Robert M. Department of Internal Medicine Carver College of Medicine 23
15 Spitz, Douglas R. Department of Radiation Oncology Free Radical and Radiation Biology Program 130
16 Shea, Madeline A. Department of Biochemistry Carver College of Medicine 31
17 Colbran, Roger J. Department of Biochemistry Vanderbilt University 87
18 Mohler, Peter J. Department of Internal Medicine Carver College of Medicine 45
19 Anderson, Mark E. Department of Internal Medicine; Department of Molecular Physiology and Biophysics Carver College of Medicine 94
2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997 1996
loading issue ...
Floating div contents here